BioTime is a biotechnology company focused on the emerging field of regenerative medicine. Our core technologies center on novel stem cells capable of becoming all of the cell types in the human body. Products made from these “pluripotent” stem cells are being developed by our subsidiaries, each of which concentrates on different medical specialties, including: neuroscience, oncology, orthopedics, and blood and vascular diseases. BioTime’s commercial strategy targets near-term commercial opportunities such as Hextend and our current line of research products: ACTCellerate cell lines and associated ESpan culture media, HyStem hydrogels, and GMP human embryonic stem cell lines. In addition, the ...
BioTime is a biotechnology company focused on the emerging field of regenerative medicine. Our core technologies center on novel stem cells capable of becoming all of the cell types in the human body. Products made from these “pluripotent” stem cells are being developed by our subsidiaries, each of which concentrates on different medical specialties, including: neuroscience, oncology, orthopedics, and blood and vascular diseases. BioTime’s commercial strategy targets near-term commercial opportunities such as Hextend and our current line of research products: ACTCellerate cell lines and associated ESpan culture media, HyStem hydrogels, and GMP human embryonic stem cell lines. In addition, the launch of HyStem-Rx as a cell delivery device is expected in 2013, and the launch of PanC-Dx as a novel blood-based cancer screen is expected by 2014.
-
Number of Employees:
0-25
-
Annual Revenue:
$1-10 Million